Improving clinical trial design for Duchenne muscular dystrophy.

Item

http://www.wikidata.org/entity/Q35755174

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Improving clinical trial design for Duchenne muscular dystrophy.

@ast

Improving clinical trial design for Duchenne muscular dystrophy.

@en

type

Item

label

Improving clinical trial design for Duchenne muscular dystrophy.

@ast

Improving clinical trial design for Duchenne muscular dystrophy.

@en

prefLabel

Improving clinical trial design for Duchenne muscular dystrophy.

@ast

Improving clinical trial design for Duchenne muscular dystrophy.

@en

P1476

Improving clinical trial design for Duchenne muscular dystrophy

@en

P2093

Patrizia Sabatelli

http://www.w3.org/2001/XMLSchema#string

P2860

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits

Dystrophin as a therapeutic biomarker: are we ignoring data from the past?

What Can We Learn From Clinical Trials of Exon Skipping for DMD?

The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an

Systemic administration of PRO051 in Duchenne's muscular dystrophy.

The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy

Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

P2888

s12883-015-0408-z

P304

153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12883-015-0408-Z

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luciano Merlini

P577

2015-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281310041

http://www.w3.org/2001/XMLSchema#string

P6179

1030960599

http://www.w3.org/2001/XMLSchema#string

P698

26306629

http://www.w3.org/2001/XMLSchema#string

P932

4549867

http://www.w3.org/2001/XMLSchema#string